Editorial review
Educational content is reviewed for source quality, clinical boundaries, and readability. It is not medical advice; confirm care decisions with a licensed clinician.
What a Ketamine Consent Form Should Cover
A ketamine treatment consent form should state clearly whether your prescription is FDA-approved or off-label, list the specific risks and monitoring plan for your session, name the drug and route being used, and spell out your right to stop treatment at any time. Before you sign, ask your provider to walk through each section out loud rather than handing you a form to sign in the waiting room.
Only esketamine (Spravato), a nasal spray formulation of the S-enantiomer of ketamine, holds FDA approval, and only for treatment-resistant depression in adults alongside an oral antidepressant. Generic ketamine, whether given by IV, intramuscular injection, oral lozenge, or at-home sublingual troche, is prescribed off-label for depression, anxiety, PTSD, and other conditions, meaning the FDA has not reviewed it for those specific uses. A consent form that doesn't mention this distinction is missing a basic disclosure you're entitled to.
Quick Answer
Before signing a ketamine consent form, ask whether your use is FDA-approved (esketamine/Spravato) or off-label (generic ketamine), what specific risks and side effects apply to your dose and route, how you'll be monitored during and after each session, who you can contact in an emergency, and whether you can stop treatment at any point without penalty. A provider should answer these in plain language, not just point you to a document.
Why the Off-Label Disclosure Matters
The FDA requires esketamine to be dispensed only under a Risk Evaluation and Mitigation Strategy (REMS), a program requiring monitored dosing and documented consent because of sedation and dissociation risks observed in clinical trials. Generic ketamine used off-label isn't bound by that same federal program, so the thoroughness of consent and monitoring depends on the individual clinic or telehealth provider you choose. That's one reason the questions you ask matter as much as the form itself; two providers can hand you very different paperwork for the same drug.
If you're still deciding whether ketamine fits your situation, start with our guide to ketamine treatment eligibility questions and our broader list of questions to ask before ketamine therapy before you get to the paperwork stage.
Compare your options before deciding
See route, setting, cost, and safety differences before your next provider conversation.
Compare treatment optionsAsk Before You Sign
- Is this use of ketamine FDA-approved or off-label for my condition?
- What specific risks (blood pressure changes, dissociation, bladder issues with long-term use, dependence potential) apply to my dose and route?
- Who will monitor me during the session, and what's the plan if my blood pressure or heart rate spikes?
- What's the emergency protocol if I have a reaction after I leave the clinic or after an at-home dose?
- Can I stop treatment at any time without losing a deposit or being penalized?
- Does the form name the specific drug, dose range, and route, or is it generic boilerplate?
- Has the provider documented the alternatives I was offered, including therapy or other medications?
- Who has access to my signed consent record, and how is it stored?
Red Flags in a Consent Form
Walk away, or ask more questions, if the form is vague about dosing, doesn't name a specific licensed prescriber, or asks you to sign before you've met with a clinician. A consent form that bundles broad risk-assumption language without describing what those risks actually are isn't informed consent, it's a liability waiver. You're also entitled to ask your prescriber directly; see our list of questions to ask a psychiatrist about ketamine therapy for what to raise in that conversation.
For telehealth ketamine programs, confirm the prescriber is licensed in your state using the steps in our guide on how to verify a ketamine provider's medical license, and check that the practice follows Ryan Haight Act telehealth prescribing requirements for controlled substances. Ketamine is a Schedule III controlled substance under the federal Controlled Substances Act, and consent paperwork for at-home or telehealth dosing should reflect the added safety planning that comes with less direct in-person supervision.
If a Form Feels Rushed
If you're asked to sign a consent form in the waiting room with no time to read it or ask questions, that's a sign to slow down. Informed consent means you understood what you signed, not just that you signed it. You can ask for a copy to review at home before your first session.
Not Sure What Else to Ask?
Review a full list of questions for your first consultation and follow-up visits before you commit to a provider.
Frequently Asked Questions
Yes, and a provider acting in good faith should send it to you in advance. Reading it at home, without time pressure, gives you a real chance to ask follow-up questions before your first session.
No. A properly written consent form should state that you can stop treatment at any point. If a form implies you've waived the right to discontinue, ask the provider to clarify or correct it before you sign.
Ask the prescriber directly whether your treatment is FDA-approved esketamine or off-label generic ketamine. Only esketamine (Spravato) carries FDA approval, and for treatment-resistant depression specifically; every other use is off-label and should be disclosed as such.
They should address different risks. At-home sublingual or oral programs typically add sections on who can be present during dosing, how to reach the care team if something feels wrong, and what to do if blood pressure or mood symptoms worsen between visits, since there's no clinical staff physically present.
Share
Related Reading
Need help or want to reach readers?
Have a correction, provider question, or advertising inquiry? Reach the editorial team.